PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that the Department of Orthopaedics and Traumatology at the Chinese University of Hong Kong (CUHK) is the first hospital in China to install the EOS system.
Since its founding in 1982, the mission of CUHK’s orthopedics department has evolved into a commitment to provide the highest quality service in patient care, research, education and teaching for medical students and postgraduate training. The department’s clinical work and research has been published in more than 54 international medical journals, contributing to CUHK ranking among the top 100 medical schools in the world, according to Thompson Reuters’, “Times Higher Education World University Subjects Rankings”1.
The university’s decision to adopt an EOS system was guided by the orthopaedic department’s emphasis on patient care and a curriculum designed to train surgeons on industry leading equipment and innovative surgical planning and modeling services.
Prof. Jack Chun-yiu Cheng, Chairman of the Department of Orthopaedics and Traumatology, said, “The orthopaedic clinic at CUHK ceaselessly endeavors to serve the needs and improve the well-being of the patients in Hong Kong and in the global community. By adopting the EOS imaging system, we not only deliver an unmatched standard of care for our patients, but we also ensure that medical students and training surgeons have access to the gold standard in low dose 2D/3D imaging.”
Marie Meynadier, CEO of EOS imaging, said, “The Chinese University of Hong Kong is ranked as a leading university for orthopedic care in Asia and we are thrilled by their decision to adopt EOS® for their diagnosis, planning and control imaging. Adoption of low dose 2D/3D imaging continues to increase in Asia, and this new installation will continue to strengthen our presence in this large and important market.”
The EOS® system provides full-body stereoradiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Available) by bringing pediatric spine follow up exams at the dose level equivalent to a week of natural background radiation on Earth.
For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: July 21th, 2015
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 47 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.